ICI-based combinations for advanced/metastatic renal cell carcinoma: Highlights from ASCO GU 2023

touchCONGRESS for touchONCOLOGY Listen to renowned renal cell carcinoma (RCC) expert Prof. Brian Rini review key data presented at the ASCO GU 2023 congress on advances in immune checkpoint inhibitor (ICI)-based regimens for RCC. He also discusses with two additional leading RCC experts, Prof. Elizabeth Plimack and Prof. Thomas Powles, how these data may apply in clinical practice. Overview: Data reviews with Prof. Brian Rini Expert panel discussions with Prof. Brian Rini, Prof. Elizabeth Plimack and Prof. Thomas Powles on the themes below Clinical themes: ICI-based combinations in the treatment of advanced/metastatic RCC: What do the latest efficacy and safety data show? What is the potential role of biomarkers in predicting response to ICI-based combinations in patients with advanced/metastatic RCC? How might the latest data for ICI-based combinations for advanced/metastatic RCC be implemented in clinical practice? The internationally renowned RCC expert faculty: Prof. Brian Rini, Vanderbilt University Medical Center, Nashville, TN, USA Prof. Elizabeth Plimack, Fox Chase Cancer Center, Philadelphia, PA, USA Prof. Thomas Powles, Barts Cancer Centre, St Bartholomew’s Hospital, London, UK This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from Merck & Co. Inc. and Exelixis Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/congress-renal-cell-carcinoma-asco-gu-2023/